{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:49:25Z","timestamp":1771490965555,"version":"3.50.1"},"reference-count":22,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Antiarrhythmic therapy for recurrent ventricular arrhythmias (VAs) in patients having undergone catheter ablation and in whom amiodarone and\/or beta-blockers were ineffective or contraindicated is a controversial issue. Purpose: The present study sought to compare the efficacy and tolerability of oral procainamide and mexiletine in patients with recurrent ventricular arrhythmias when the standard therapy strategy failed. Methods: All patients with an implantable cardioverter defibrillator (ICD) treated with oral procainamide or mexiletine for recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) in two cardiology divisions between January 2010 and January 2020 were enrolled. Patients were divided into group A (oral procainamide) and group B (mexiletine) and the two groups were compared to each other. The primary endpoint was the efficacy of therapy; the secondary endpoint was the discontinuation of therapy. All events that occurred during procainamide or mexiletine treatment were compared with a matched duration period before the initiation of the therapy. Antiarrhythmic therapy was considered effective when a \u226580% reduction of the sustained ventricular arrhythmias burden recorded by the ICD was achieved. Results: A total of 68 consecutive patients (61 males, 89.7%; mean age 74 \u00b1 10 years) were included in this retrospective analysis. After a median follow-up of 19 months, 38 (56%) patients had a significant reduction in the VA burden. After multivariable adjustment, therapy with procainamide was independently associated with an almost 3-fold higher efficacy on VA suppression compared to mexiletine (HR 2.54, 95% CI 1.06\u20136.14, p = 0.03). Only three patients (9%) treated with procainamide presented severe side effects (dyspnea or hypotension) requiring discontinuation of therapy compared with six patients (18%) treated with mexiletine who interrupted therapy because of severe side effects (p = 0.47). Conclusions: Compared to mexiletine, oral procainamide had a higher efficacy for the treatment of recurrent and refractory VAs, and showed a good profile of tolerability.<\/jats:p>","DOI":"10.3390\/jcm13206099","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:44:31Z","timestamp":1728909871000},"page":"6099","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Oral Procainamide and Mexiletine Treatment of Recurrent and Refractory Ventricular Tachyarrhythmias"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1005-7612","authenticated-orcid":false,"given":"Mauro","family":"Toniolo","sequence":"first","affiliation":[{"name":"Division of Cardiology, University Hospital \u201cS.Maria della Misericordia\u201d, P.le S.Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-5988","authenticated-orcid":false,"given":"Daniele","family":"Muser","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University Hospital \u201cS.Maria della Misericordia\u201d, P.le S.Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Mugnai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Vicenza General Hospital, 36071 Arzignano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Rebellato","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University Hospital \u201cS.Maria della Misericordia\u201d, P.le S.Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Daleffe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University Hospital \u201cS.Maria della Misericordia\u201d, P.le S.Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Bilato","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Vicenza General Hospital, 36071 Arzignano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University Hospital \u201cS.Maria della Misericordia\u201d, P.le S.Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1099-5129(03)00078-3","article-title":"Implantable cardioverter defibrillator recipients: Quality of life in recipients with and without ICD shock delivery: A prospective study","volume":"5","author":"Kamphuis","year":"2003","journal-title":"Europace"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1161\/01.CIR.0000150390.04704.B7","article-title":"Multicenter Automatic Defibrillator Implantation. Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator","volume":"110","author":"Moss","year":"2004","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1540-8159.2006.00409.x","article-title":"Depression and anxiety status of patients with implantable cardioverter defibrillator and precipitating factors","volume":"29","author":"Bilge","year":"2006","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa071098","article-title":"Prognostic importance of defibrillator shocks in patients with heart failure","volume":"359","author":"Poole","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/eurheartj\/eht451","article-title":"Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT","volume":"35","author":"Sood","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(73)92270-8","article-title":"Treatment of ventricular arrhythmias with mexiletine","volume":"302","author":"Talbot","year":"1973","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Impact Research Group (1984). International Mexiletine Placebo Antiarrhythmic Coronary Trial: I. Report on arrhythmia and other findings. J. Am. Coll. Cardiol., 4, 1148\u20131163.","DOI":"10.1016\/S0735-1097(84)80133-3"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/01.CIR.4.1.13","article-title":"The use of procainamide in cardiac arrhythmias","volume":"4","author":"Kayden","year":"1951","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.CIR.15.1.118","article-title":"Procainamide: A review","volume":"15","author":"Kayden","year":"1957","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.1984.tb14519.x","article-title":"Procainamide: Clinical pharmacology and efficacy against ventricular arrhythmias","volume":"432","author":"Giardina","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Pediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/europace\/euac087","article-title":"Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: A systematic review","volume":"24","author":"Rosenberg","year":"2022","journal-title":"Europace"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/00015385.2021.1926628","article-title":"Mexiletine for ventricular arrhythmias in patient with chronic coronary syndrome: A cohort study","volume":"77","author":"Mugnai","year":"2021","journal-title":"Acta Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.hroo.2021.10.002","article-title":"Oral procainamide as pharmacological treatment of recurrent and refractory ventricular tachyarrhythmias: A single center experience","volume":"2","author":"Toniolo","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/j.cjca.2014.07.739","article-title":"Oral procainamide in patients with structural heart disease and refractory ventricular tachycardia","volume":"30","author":"Steinberg","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"euae049","DOI":"10.1093\/europace\/euae049","article-title":"Management of patients with an electrical storm or clustered ventricular arrhythmias: A clinical consensus statement of the European Heart Rhythm Association of the ESC-endorsed by the Asia-Pacific Heart Rhythm Society, Heart Rhythm Society, and Latin-American Heart Rhythm Society","volume":"26","author":"Lenarczyk","year":"2024","journal-title":"Europace"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(75)92548-9","article-title":"Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction","volume":"1","author":"Campbell","year":"1975","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0002-8703(85)90186-3","article-title":"Mexiletine: Double-blind comparison with procainamide in PVC suppression and open-label sequential comparison with amiodarone in life-threatening ventricular arrhythmias","volume":"110","author":"Nademanee","year":"1985","journal-title":"Am. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF03085967","article-title":"Antiarrhythmic drugs, patients, and the pharmaceutical industry: Value for patients, physicians, pharmacists or shareholders?","volume":"15","author":"Wilde","year":"2007","journal-title":"Neth. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1540-8159.1991.tb04090.x","article-title":"The Role of Combination Therapy with Mexiletine and Procainamide in Patients with Inducible Sustained Ventricular Tachycardia Refractory to Intravenous Procainamide","volume":"14","author":"Widerhorn","year":"1991","journal-title":"Pacing Clin. Electrophysiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6099\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:29Z","timestamp":1760112749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,13]]},"references-count":22,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13206099"],"URL":"https:\/\/doi.org\/10.3390\/jcm13206099","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,13]]}}}